Developing breakthrough AXL therapeutics to improve patients' lives

Developing breakthrough AXL therapeutics to improve patients' lives
Background
DecorationDecoration

Learn About Us

Latest news

Old woman

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections

Recent News

CEO Martin Olin steps down

BerGenBio ASA: Minutes from Extraordinary General Meeting

BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

BERGENBIO ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING

BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference

BerGenBio Second Quarter Results 2024: Solid clinical and financial progress

BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer

BerGenBio ASA: Registration of share capital reduction

BerGenBio ASA: Invitation to second quarter and half year 2024 results webcast